<DOC>
	<DOCNO>NCT00064623</DOCNO>
	<brief_summary>The purpose study determine investigational drug , NGX-4010 ( high-concentration capsaicin patch ) , effective treat painful HIV-associated neuropathy .</brief_summary>
	<brief_title>Study NGX-4010 Treatment Painful HIV-Associated Neuropathy</brief_title>
	<detailed_description>The C107 study randomize , double-blind , control dose finding study NGX-4010 treatment painful symptom HIV-associated neuropathy . Participants randomly assign receive initial treatment accord one three dos ( application duration ) , receive double-blind NGX-4010 patch ( high-concentration capsaicin ) match control ( low-concentration capsaicin ) . Participants complete study evaluation Week 12 option receive 3 additional open-label treatment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>At least 18 year age Documented evidence HIV1 infection Documented diagnosis painful HIVassociated distal symmetrical polyneuropathy establish neurologist result HIV disease and/or antiretroviral drug exposure , primary symptom pain , burn dysesthetic discomfort foot least 2 month prior Screening Visit , absent diminish ankle reflex , least one following : distal diminution vibration sensation pain temperature sensation legs Either neurotoxic antiretroviral ( didanosine , zalcitabine stavudine ) exposure least 8 week prior Screening Visit , currently stable dose ( ) neurotoxic antiretroviral ( ) least 8 week prior Screening Visit Screening Pain Sum Score 12 36 Karnofsky Performance Score great equal 60 Intact , unbroken skin painful area ( ) treat If take chronic pain medication , stable ( PRN ) regimen least 21 day prior Treatment Visit willing maintain medication stable dose ( ) schedule throughout study Female subject childbearing potential : negative serum pregnancy test perform Screening Visit Willing use effective method birth control and/or refrain participate conception process study 30 day follow experimental drug exposure Willing able comply protocol requirement duration study Concomitant opioid medication , unless orally transdermally administer exceed total daily dose morphine 60 mg/day , equivalent . Parenteral opioid use exclude , regardless dose Unavailability effective rescue medication strategy subject , unwillingness use opioid analgesic treatment , high tolerance opioids preclude ability relieve treatmentassociated discomfort Roxicodone® Vicodin® , judge Investigator Active substance abuse history chronic substance abuse within past year , prior chronic substance abuse judge likely recur study period investigator Recent use ( within 21 day precede Treatment Visit topically apply pain medication , nonsteroidal antiinflammatory drug , menthol , methyl salicylate , local anesthetic ( include Lidoderm® ) , steroid capsaicin product painful area Current use investigational agent Class 1 antiarrhythmic drug Significant pain etiology painful HIVassociated neuropathy ; significant ongoing pain cause ( ) may interfere judge HIVassociated neuropathy pain Evidence another contributing cause peripheral neuropathy , e.g. , diabetes mellitus require medication control ( i.e. , oral hypoglycemics , insulin ) ; hereditary neuropathy ; vitamin B12 deficiency ( B12 level ≤ 200 pg/mL ) less 3 month B12 supplementation prior Screening Visit ; treatment within 90 day prior Screening Visit drug may contribute sensory neuropathy Any implant medical device ( spinal cord stimulator , intrathecal pump peripheral nerve stimulator ) treatment neuropathic pain Treatment acute opportunistic infection within 14 day Treatment Visit Presence acute , active opportunistic infection , except oral thrush ; oral , genital , rectal herpes ; Mycobacterium avium bacteremia within 2 week prior Screening Visit Currently active malignant disease Significant ongoing untreated abnormality cardiac , renal , hepatic , pulmonary function may interfere either ability complete study evaluation adverse event Hypersensitivity capsaicin ( i.e. , chili pepper OTC capsaicin product ) , local anesthetic , Roxicodone® , Vicodin® , adhesive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Dermal assessment</keyword>
	<keyword>Pain measurement</keyword>
	<keyword>Diary</keyword>
	<keyword>Analgesics/*therapeutic use</keyword>
	<keyword>Capsaicin/*administration &amp; dosage/adverse effect</keyword>
	<keyword>HIV Infections/*complications/*drug therapy</keyword>
	<keyword>Peripheral Nervous System Diseases/*complications/diagnosis/*therapy</keyword>
	<keyword>Peripheral Nervous System Diseases/drug therapy/*etiology/physiopathology</keyword>
</DOC>